Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. (Nasdaq: WVE) is a clinical-stage biotechnology company focused on RNA medicines, and its news flow reflects active development across multiple programs and financing activities. Company press releases frequently highlight progress from its PRISM RNA medicines platform, which supports modalities such as RNA interference, RNA editing, splicing, and antisense silencing.
Investors following WVE news can expect regular updates on Wave’s key clinical programs. These include WVE-007, an investigational INHBE GalNAc-siRNA for obesity studied in the INLIGHT trial, where the company has reported dose-dependent reductions in serum Activin E and interim body composition data. News items also cover WVE-006, an RNA editing AIMer for alpha-1 antitrypsin deficiency in the RestorAATion-2 trial, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington’s disease, including data on allele-selective reduction of mutant huntingtin.
Wave’s press releases also address corporate and financial developments, such as public offerings of ordinary shares and pre-funded warrants under its shelf registration statement, quarterly financial results, and updates on expected cash runway. Additional news covers participation in major healthcare and investor conferences, including presentations at the J.P. Morgan Healthcare Conference, ObesityWeek, and other industry events, where the company shares preclinical and clinical data as well as strategic priorities.
This news page aggregates these disclosures so readers can review clinical milestones, regulatory interactions, financing transactions, and corporate presentations related to Wave Life Sciences in one place. For those tracking WVE, it provides a centralized view of how the company’s RNA medicines pipeline and capital strategy evolve over time.
Wave Life Sciences (Nasdaq: WVE) announced a conference call scheduled for 8:30 a.m. ET on November 10, 2022, to discuss its Q3 2022 financial results and provide a business update. The call will be accessible via the company’s investor relations webpage. Wave Life Sciences is a clinical-stage genetic medicines company focused on developing treatments for severe diseases using its proprietary PRISM platform for drug development. The archived call will also be available post-event.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced its participation in upcoming scientific conferences to showcase advancements in oligonucleotide chemistry and RNA editing. This includes preclinical data for WVE-006, targeting alpha-1 antitrypsin deficiency, which is presented for the first time. The presentations at the Oligonucleotide Therapeutics Society and European Society of Gene & Cell Therapy meetings will emphasize the company's proprietary discoveries and drug development capabilities.
Wave Life Sciences highlighted its advanced candidate, WVE-006, for treating alpha-1 antitrypsin deficiency (AATD) during a recent virtual event. The RNA editing program aims to correct genetic mutations and restore functional protein levels. Preclinical data show a significant increase in AAT protein production and functional activity. Clinical trial applications for WVE-006 are expected to be submitted in 2023. Wave is also exploring broader applications for its AIMers technology beyond AATD, potentially impacting multiple diseases.
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will participate in an analyst-led fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 3:15 p.m. ET in New York City. A live webcast of the event will be accessible on the company's Investor Relations page, with a replay available for a limited time afterward. Wave Life Sciences focuses on developing innovative treatments for genetically defined diseases through its proprietary PRISM platform.
Wave Life Sciences Ltd. announces positive results from the SELECT-HD Phase 1b/2a clinical trial of WVE-003, a candidate for treating Huntington’s disease. Single doses of 30 or 60 mg led to a mean reduction of 22% in mutant huntingtin protein levels in cerebrospinal fluid, with a median reduction of 30%. The treatment was reportedly well-tolerated, with no serious adverse events. Wave plans to expand the dosing cohorts and has early data supporting allele-selective knockdown of the harmful protein. Further updates are expected in 1H 2023.
Wave Life Sciences (Nasdaq: WVE) announced an analyst and investor webcast on September 28, 2022, focusing on WVE-006, its first-in-class RNA editing candidate targeting alpha-1 antitrypsin deficiency (AATD). The event, titled 'Towards the Clinic: Spotlight on RNA Editing for AATD', will provide insights from AATD expert Dr. D. Kyle Hogarth and the Wave management team. WVE-006 aims to correct mutations in the SERPINA1 gene, addressing both lung and liver disease. Registration is available on Wave's website.
Wave Life Sciences (WVE) announced the selection of WVE-006 as its first RNA editing candidate for treating alpha-1 antitrypsin deficiency (AATD), with clinical trial applications expected in 2023. The company reported a net loss of $41.3 million for Q2 2022, down from $38.8 million a year earlier, with revenue declining to $0.4 million. Research and development expenses were $29.7 million, while general and administrative expenses increased to $12.8 million. A successful financing round in June 2022 raised $70 million, strengthening the balance sheet and providing cash runway until the end of 2023.
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call on August 11, 2022, at 8:30 a.m. ET to review its Q2 2022 financial results and provide a business update. Investors can access the webcast through the company's investor relations website. Analysts are encouraged to register in advance for the Q&A session. Wave Life Sciences focuses on developing genetic medicines for severe diseases, using its proprietary PRISM platform to create stereopure oligonucleotides.
Wave Life Sciences (Nasdaq: WVE) announced an underwritten offering of 25,464,483 ordinary shares at $2.15 each, representing a 7.5% premium over the June 13 closing price. Additionally, when issuing pre-funded warrants to buy 7,093,656 shares at $2.1499, they aim to raise approximately $70 million. The offering will close around June 16, 2022, subject to customary conditions. RA Capital Management is a notable participant, with SVB Securities acting as the bookrunning manager. The offering is made under a previously approved SEC registration statement.
Wave Life Sciences (Nasdaq: WVE) announced that its CEO, Paul Bolno, will participate in an analyst-led fireside chat at the 2022 Jefferies Healthcare Conference in New York City on June 8, 2022, at 3:00 p.m. ET. A live webcast will be available on Wave's Investor Relations page, with a replay accessible for a limited time after the event. Wave Life Sciences is focused on developing genetic medicines for serious diseases using its proprietary PRISM platform.